Concise Review: Cell-Based Therapies and Other Non-Traditional Approaches for Type 1 Diabetes

Remi J. Creusot, Manuela Battaglia, Maria Grazia Roncarolo, C. Garrison Fathman

Research output: Contribution to journalArticle

Abstract

The evolution of Type 1 diabetes (T1D) therapy has been marked by consecutive shifts, from insulin replacement to immunosuppressive drugs and targeted biologics (following the understanding that T1D is an autoimmune disease), and to more disease-specific or patient-oriented approaches such as antigen-specific and cell-based therapies, with a goal to provide efficacy, safety, and long-term protection. At the same time, another important paradigm shift from treatment of new onset T1D patients to prevention in high-risk individuals has taken place, based on the hypothesis that therapeutic approaches deemed sufficiently safe may show better efficacy if applied early enough to maintain endogenous β cell function, a concept supported by many preclinical studies. This new strategy has been made possible by capitalizing on a variety of biomarkers that can more reliably estimate the risk and rate of progression of the disease. More advanced ("omic"-based) biomarkers that also shed light on the underlying contributors of disease for each individual will be helpful to guide the choice of the most appropriate therapies, or combinations thereof. In this review, we present current efforts to stratify patients according to biomarkers and current alternatives to conventional drug-based therapies for T1D, with a special emphasis on cell-based therapies, their status in the clinic and potential for treatment and/or prevention.

Original languageEnglish
JournalStem Cells
DOIs
Publication statusAccepted/In press - 2016

Fingerprint

Cell- and Tissue-Based Therapy
Type 1 Diabetes Mellitus
Biomarkers
Therapeutics
Immunosuppressive Agents
Biological Products
Autoimmune Diseases
Disease Progression
Insulin
Safety
Antigens
Drug Therapy
Pharmaceutical Preparations

Keywords

  • Antigen-specific
  • Autoimmunity
  • Cell therapy
  • Immunoregulation
  • Prevention
  • T cells
  • Type 1 diabetes

ASJC Scopus subject areas

  • Cell Biology
  • Developmental Biology
  • Molecular Medicine

Cite this

Concise Review : Cell-Based Therapies and Other Non-Traditional Approaches for Type 1 Diabetes. / Creusot, Remi J.; Battaglia, Manuela; Roncarolo, Maria Grazia; Fathman, C. Garrison.

In: Stem Cells, 2016.

Research output: Contribution to journalArticle

@article{0c32493be4584dd9ba4ccaf9ef7ac49e,
title = "Concise Review: Cell-Based Therapies and Other Non-Traditional Approaches for Type 1 Diabetes",
abstract = "The evolution of Type 1 diabetes (T1D) therapy has been marked by consecutive shifts, from insulin replacement to immunosuppressive drugs and targeted biologics (following the understanding that T1D is an autoimmune disease), and to more disease-specific or patient-oriented approaches such as antigen-specific and cell-based therapies, with a goal to provide efficacy, safety, and long-term protection. At the same time, another important paradigm shift from treatment of new onset T1D patients to prevention in high-risk individuals has taken place, based on the hypothesis that therapeutic approaches deemed sufficiently safe may show better efficacy if applied early enough to maintain endogenous β cell function, a concept supported by many preclinical studies. This new strategy has been made possible by capitalizing on a variety of biomarkers that can more reliably estimate the risk and rate of progression of the disease. More advanced ({"}omic{"}-based) biomarkers that also shed light on the underlying contributors of disease for each individual will be helpful to guide the choice of the most appropriate therapies, or combinations thereof. In this review, we present current efforts to stratify patients according to biomarkers and current alternatives to conventional drug-based therapies for T1D, with a special emphasis on cell-based therapies, their status in the clinic and potential for treatment and/or prevention.",
keywords = "Antigen-specific, Autoimmunity, Cell therapy, Immunoregulation, Prevention, T cells, Type 1 diabetes",
author = "Creusot, {Remi J.} and Manuela Battaglia and Roncarolo, {Maria Grazia} and Fathman, {C. Garrison}",
year = "2016",
doi = "10.1002/stem.2290",
language = "English",
journal = "Stem Cells",
issn = "1066-5099",
publisher = "AlphaMed Press",

}

TY - JOUR

T1 - Concise Review

T2 - Cell-Based Therapies and Other Non-Traditional Approaches for Type 1 Diabetes

AU - Creusot, Remi J.

AU - Battaglia, Manuela

AU - Roncarolo, Maria Grazia

AU - Fathman, C. Garrison

PY - 2016

Y1 - 2016

N2 - The evolution of Type 1 diabetes (T1D) therapy has been marked by consecutive shifts, from insulin replacement to immunosuppressive drugs and targeted biologics (following the understanding that T1D is an autoimmune disease), and to more disease-specific or patient-oriented approaches such as antigen-specific and cell-based therapies, with a goal to provide efficacy, safety, and long-term protection. At the same time, another important paradigm shift from treatment of new onset T1D patients to prevention in high-risk individuals has taken place, based on the hypothesis that therapeutic approaches deemed sufficiently safe may show better efficacy if applied early enough to maintain endogenous β cell function, a concept supported by many preclinical studies. This new strategy has been made possible by capitalizing on a variety of biomarkers that can more reliably estimate the risk and rate of progression of the disease. More advanced ("omic"-based) biomarkers that also shed light on the underlying contributors of disease for each individual will be helpful to guide the choice of the most appropriate therapies, or combinations thereof. In this review, we present current efforts to stratify patients according to biomarkers and current alternatives to conventional drug-based therapies for T1D, with a special emphasis on cell-based therapies, their status in the clinic and potential for treatment and/or prevention.

AB - The evolution of Type 1 diabetes (T1D) therapy has been marked by consecutive shifts, from insulin replacement to immunosuppressive drugs and targeted biologics (following the understanding that T1D is an autoimmune disease), and to more disease-specific or patient-oriented approaches such as antigen-specific and cell-based therapies, with a goal to provide efficacy, safety, and long-term protection. At the same time, another important paradigm shift from treatment of new onset T1D patients to prevention in high-risk individuals has taken place, based on the hypothesis that therapeutic approaches deemed sufficiently safe may show better efficacy if applied early enough to maintain endogenous β cell function, a concept supported by many preclinical studies. This new strategy has been made possible by capitalizing on a variety of biomarkers that can more reliably estimate the risk and rate of progression of the disease. More advanced ("omic"-based) biomarkers that also shed light on the underlying contributors of disease for each individual will be helpful to guide the choice of the most appropriate therapies, or combinations thereof. In this review, we present current efforts to stratify patients according to biomarkers and current alternatives to conventional drug-based therapies for T1D, with a special emphasis on cell-based therapies, their status in the clinic and potential for treatment and/or prevention.

KW - Antigen-specific

KW - Autoimmunity

KW - Cell therapy

KW - Immunoregulation

KW - Prevention

KW - T cells

KW - Type 1 diabetes

UR - http://www.scopus.com/inward/record.url?scp=84958259403&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84958259403&partnerID=8YFLogxK

U2 - 10.1002/stem.2290

DO - 10.1002/stem.2290

M3 - Article

AN - SCOPUS:84958259403

JO - Stem Cells

JF - Stem Cells

SN - 1066-5099

ER -